Warning Letter Wednesday Posts
A weekly exploration of FDA warning letters and enforcement trends
Takeaway -
Marketing strategies should consider “reasonable consumer expectations” to avoid issues
Takeaway -
Functional mushroom products under increased scrutiny
Takeaway -
NAD challenge cases explored
Takeaway -
Nutrition fact panels must be in a compliant format
Takeaway -
Free products should also be disclosed
Takeaway -
Product reviews are marketing claims
Takeaway -
Following SOPs is essential to compliance
Takeaway -
Discussing ingredient benefits is "marketing"
Takeaway -
Don’t engage with risky reviews
Takeaway -
Playful ads can attract scrutiny
Takeaway -
Well intentioned marketing claims can turn products into high-risk regulatory categories
Takeaway -
Learn from other’s mistakes